- Market Capitalization, $K 314,956
- Shares Outstanding, K 88,720
- Annual Sales, $ 1,720 K
- Annual Income, $ -40,490 K
- 60-Month Beta 2.19
- Price/Sales 191.48
- Price/Cash Flow N/A
- Price/Book 8.09
|Period||Period Low||Period High||Performance|
| || |
+0.11 (+3.20%)since 08/24/21
| || |
+0.51 (+16.78%)since 06/24/21
| || |
+2.49 (+234.91%)since 09/24/20
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which...
--- Brian Schwartz, M.D., transitioning from Consulting Chief Physician to Infinity's Board of Directors -
Investors need to pay close attention to Infinity Pharmaceuticals (INFI) stock based on the movements in the options market lately.
Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology...
Morning Markets Sep S&P 500 futures this morning are up +0.41% on optimism about Q2 corporate earnings results. Stocks are also garnering support from the improved prospects that the Senate will pass...
Infinity (INFI) delivered earnings and revenue surprises of 0.00% and 30.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass. (AP) _ Infinity Pharmaceuticals Inc. (INFI) on Tuesday reported a loss of $11.3 million in its second quarter.
--- MARIO-3 TNBC early data suggest the addition of eganelisib to standard of care regimens extends progression free survival regardless of PD-L1 status with majority of patients still on treatment -
--- Increases seen in overall survival in 2L urothelial cancer (UC) and in progression free survival in 1L triple negative breast cancer (TNBC), in both cases regardless of PD-L1 status -
Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
|Alps Medical Breakthroughs ETF|
|Micro-Cap Ishares ETF|
|Principal Healthcare Innovators Index|
|GS Activebeta U.S. Small Cap Equity ETF|
|U.S. Momentum Factor Vanguard ETF|